Compare Costco Wholesale Corporation (COST) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Quest Diagnostics Inc — how do they compare? Costco Wholesale Corporation trades at $946.4 (market cap $420.05B), while Quest Diagnostics Inc trades at $229.97 (market cap $25.48B). The key difference: Costco Wholesale Corporation is far larger — about 16.5× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Quest Diagnostics Inc for 56 Days on average.
| COST | DGX | |
|---|---|---|
Market Cap | $420.05B | $25.48B |
Volume | 2,087,565 | 941,866 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $247.45 |
52-Week Low | $849.63 | $173.49 |
Typical Hold Time | 133 Days | 56 Days |
Enterprise Value | $407.33B | $31.23B |
Dividend Yield | 0.62% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $946.92, up 0.5% today, near its pivot point of $947. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, revenue grew to $275.24B in 2025 with a net income margin of 3.04%, while the P/E ratio of 45.66 reflects a premium valuation. Recent news highlights strong March sales growth of 11.3% year-over-year and a membership fee increase, signaling pricing power.
The outlook remains positive with analyst consensus strongly favoring Buy (66.1%) and a price target of $1,100, implying ~16% upside. Key risks include high valuation sensitivity and competitive pressures. Earnings growth and membership renewal rates are critical catalysts for sustained appreciation, but any miss could trigger a pullback.
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
